The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Husam Alqaisi
No Relationships to Disclose
 
David E. Cohn
Consulting or Advisory Role - Oncology Analytics
Research Funding - AbbVie (Inst); Advaxis (Inst); Agenus (Inst); Ajinomoto (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Henry Jackson Foundation (Inst); ImmunoGen (Inst); INC Research (Inst); inVentiv Health (Inst); Janssen Research & Development (Inst); Ludwig Institute for Cancer Research (Inst); Novartis (Inst); NRG Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); PRA International (Inst); Regeneron (Inst); Sanofi (Inst); Stemcentrix (Inst); Tesaro (Inst); Tricon Pharmaceuticals (Inst)
Other Relationship - Elsevier; UpToDate
 
Jing-Yi Chern
Consulting or Advisory Role - eviCore healthcare; Seagen
Speakers' Bureau - AstraZeneca/Merck
 
Linda R. Duska
Consulting or Advisory Role - CUE Biopharma; Genentech/Roche; Inovio Pharmaceuticals; Merck
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
 
Andrea Jewell
No Relationships to Disclose
 
Bradley Corr
Consulting or Advisory Role - AstraZeneca/Merck (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novocure (Inst)
Research Funding - Clovis Oncology (Inst)
 
Ira Seth Winer
Research Funding - Oncoceutics
 
Eugenia Girda
No Relationships to Disclose
 
Marta A. Crispens
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca; Seagen
 
Neesha C. Dhani
Honoraria - AstraZeneca
 
Robert C. Grant
No Relationships to Disclose
 
Saranya Uthayakumaran
No Relationships to Disclose
 
Crystal Lee
No Relationships to Disclose
 
Valerie Bowering
No Relationships to Disclose
 
Horace Wong
No Relationships to Disclose
 
Lisa Wang
No Relationships to Disclose
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Jeffrey Moscow
No Relationships to Disclose
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research